{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-006039","form_type":"8-K","ticker":"ARDX","cik":"0001437402","company_name":"ARDELYX, INC.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.988198+00:00","generated_at":"2026-06-18T14:50:28.534344+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ardelyx reports FY2022 net loss $67.2M; IBSRELA sales $15.6M; XPHOZAH NDA resubmission expected early Q2 2023","bullets":["Net loss for FY2022 was $67.2M ($0.42/share) vs $158.2M ($1.52/share) in 2021.","IBSRELA net product sales $15.6M for FY2022, with $8.7M in Q4; consistent prescription growth.","Cash and investments $123.9M at Dec 31, 2022; $121.0M at Feb 28, 2023 (includes $20M ATM proceeds).","XPHOZAH NDA resubmission on track for early Q2 2023 after productive FDA Type A meeting.","Debt facility amended: interest-only period may extend to Mar 2025; additional $22.5M available contingent on FDA approval and revenue targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-006039","json":"https://secwatch.observer/filing/0001628280-23-006039.json","markdown":"https://secwatch.observer/filing/0001628280-23-006039.md","text":"https://secwatch.observer/filing/0001628280-23-006039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/ardx-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T14:50:28.534344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6dbeecf58d0c103932d2e474cb2864e4cc14e069","claim":"ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Continued successful launch of IBSRELA, ending FY 2022 with $15.6 million in net product sales","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6dbeecf58d0c103932d2e474cb2864e4cc14e069","claim":"ARDELYX, INC. reported financial results for fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"Full Year 2022 Financial Results • Cash Position: As of December 31, 2022, the company had total cash, cash equivalents and short-term investments of $123.9 million, as compared to total cash, cash equivalents and short-term investments of $116.7 million as of December 31, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1437402/000162828023006039/0001628280-23-006039-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}